<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124459</url>
  </required_header>
  <id_info>
    <org_study_id>A083-03</org_study_id>
    <secondary_id>ACE-083</secondary_id>
    <nct_id>NCT03124459</nct_id>
  </id_info>
  <brief_title>Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics&#xD;
      (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with Charcot-Marie-Tooth&#xD;
      Disease Type 1 and Type X (CMT1 and CMTX), to be conducted in two parts. Part 1 is&#xD;
      non-randomized, open-label, dose-escalation and Part 2 is randomized, double-blind, and&#xD;
      placebo-controlled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 (non-randomized, open-label, dose-escalation)&#xD;
&#xD;
      Part 1 will consist of up to 3 cohorts of 6 patients each and will evaluate multiple&#xD;
      ascending dose levels of ACE-083 administered bilaterally once every 3 weeks for up to 5&#xD;
      doses in the tibialis anterior (TA) muscle. Patients in each cohort will be enrolled in a&#xD;
      4-week screening period before beginning treatment.&#xD;
&#xD;
      Part 2 (randomized, double-blind, placebo-controlled) Prior to the initiation of Part 2, a&#xD;
      review of safety and efficacy data from Part 1 will be conducted by the Safety Review Team&#xD;
      (SRT) to determine the recommended dose level (maximum 250 mg/muscle). A total of up to 40&#xD;
      new patients may be enrolled and randomized (1:1 randomization) to receive either ACE 083&#xD;
      (n=20) or placebo (n=20) bilaterally by injection into both TA muscles once every 3 weeks for&#xD;
      up to 17 doses.&#xD;
&#xD;
      Study duration for Parts 1 and 2 for each patient will be approximately 24 weeks, including a&#xD;
      4-week screening period, a 12-week treatment period, and an 8-week follow-up period after the&#xD;
      last dose.&#xD;
&#xD;
      Study duration for Part 2 will be 15 months, including 4-week screening, 6 months double&#xD;
      blind placebo-controlled, 6 months open-label and 8 week follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    (Investigation of ACE-083 for use in patients with CMT is being discontinued as it did not&#xD;
    achieve functional secondary endpoints in the A083-03 trial.&#xD;
  </why_stopped>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">March 11, 2020</completion_date>
  <primary_completion_date type="Actual">March 11, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Frequency of Adverse Events</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period for Part 1 (Study Day 141).</time_frame>
    <description>Number of subjects with at least one adverse event related to treatment intervention from Part 1 of this study. Since this outcome measure was only pre-specified for Part 1, only data from the Part 1 participants is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percent Change in Muscle Volume to the End of the Double-blind Placebo-controlled Portion of the Study.</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>The percent change from baseline in volume of injected muscle, by MRI compared to the Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Change in Amount of Intramuscular Fat Tissue to the End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>The absolute change from baseline in intramuscular fat fraction of the injected muscle, by MRI compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percent Change in Muscle Strength to the End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>Percent change from baseline in strength of the injected muscle, by Quantitative Muscle Testing (QMT) compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percent Change in Muscle Function - Walk/Run Time to the End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>The percent change from baseline in functional assessments, as measured by 10-meter walk/run time when compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percent Change in Muscle Function - Walk Distance Assessed at the End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period for the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>Percent change from baseline in functional assessments, as measured by 6-minute walk distance when compared to Day 190 Assessment, is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study.</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>Change from baseline in static and dynamic balance, as measured by the Berg Balance Scale, a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of &lt; 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percent Change in Balance and Fall Risk From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>Percent change was calculated for the difference from baseline and Day 190 Assessment scores on the Berg Balance Scale. The Berg Balance Scale, is a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of &lt; 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in Clinical Examination Score From Baseline to End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>Change from baseline in the Charcot-Marie-Tooth (CMT) Examination Score, version 2 (CMTES2), a composite scoring system to assess sensory and motor impairment in subjects with CMT. The total score is a subset of the following items from the CMT neuropathy score instrument: Sensory symptoms, Motor symptoms (legs), Motor symptoms (arms), Pinprick Sensibility, Vibration, Strength (legs), and Strength (arms). Each individual item is assessed using a rating from 0 to 4 inclusive. The range of CMTES2 scores is from 0 to 28 inclusive. A higher score means a greater degree of symptom severity. The Baseline score and score on the Day 190 Assessment are reported. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percent Change in Clinical Examination Score in Baseline to End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>Percent change was calculated for the difference in the Charcot-Marie-Tooth (CMT) Examination Score (CMTES2) from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change in Patient-reported Quality of Life From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study</measure>
    <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
    <description>The absolute change from baseline in Charcot-Marie-Tooth Health Index (CMT-HI), a disease-specific, patient-reported health index score from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Charcot-Marie-Tooth Disease</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (double-blind placebo controlled)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (open label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-083</intervention_name>
    <description>Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 3</arm_group_label>
    <arm_group_label>Part 2 (double-blind placebo controlled)</arm_group_label>
    <arm_group_label>Part 2 (open label)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Recombinant fusion protein or buffer solution</description>
    <arm_group_label>Part 2 (double-blind placebo controlled)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Diagnosis of CMT1 or CMTX confirmed by:&#xD;
&#xD;
               1. Clinical presentation and electrodiagnostics&#xD;
&#xD;
               2. Genetically-confirmed CMT1 or CMTX for the patient or first-degree relative&#xD;
&#xD;
          3. Part 1:&#xD;
&#xD;
               1. Six-minute walk distance (6MWD) of at least 150 meters (without a brace or&#xD;
                  walker)&#xD;
&#xD;
               2. Independent ambulation for at least 10 meters, without a brace&#xD;
&#xD;
               3. Left and right ankle plantar flexion MRC grade 4+ to 5, inclusive&#xD;
&#xD;
             Part 2:&#xD;
&#xD;
               1. 6MWD ≥ 150 and ≤ 500 meters (without a brace or walker); a maximum of 20% of&#xD;
                  enrolled patients with 6MWD ≥ 450 meters will be included&#xD;
&#xD;
               2. Left and right ankle plantar flexion MRC grade 4- to 5, inclusive&#xD;
&#xD;
          4. Left and right ankle dorsiflexion Medical Research Council (MRC) manual muscle testing&#xD;
             (MMT) grade 3 to 4+ inclusive. No more than 12 of the 40 subjects may have a grade of&#xD;
             3 or 3+ on one or both sides.&#xD;
&#xD;
          5. Females of childbearing potential must have negative urine pregnancy test prior to&#xD;
             enrollment and use highly effective birth control methods during study participation&#xD;
             and for 8 weeks following the last dose of ACE-083. Males must agree to use a condom&#xD;
             during any sexual contact with females of childbearing potential while participating&#xD;
             in the study and for 8 weeks following the last dose of ACE-083, even if he has&#xD;
             undergone a successful vasectomy.&#xD;
&#xD;
          6. Ability to adhere to the study visit schedule/procedures, and to understand and comply&#xD;
             with protocol requirements&#xD;
&#xD;
          7. Signed written informed consent&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          1. History of active malignancy, with the exception of fully excised or treated basal&#xD;
             cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the&#xD;
             skin&#xD;
&#xD;
          2. Symptomatic cardiopulmonary disease, significant functional impairment, significant&#xD;
             orthopedic or neuropathic pain, or other co morbidities that in the opinion of the&#xD;
             investigator would limit a patient's ability to complete strength and/or functional&#xD;
             assessments on study&#xD;
&#xD;
          3. Type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          4. Thyroid disorder unless condition is stable with no change in treatment for at least 4&#xD;
             weeks before the first dose and no expected change for duration of study&#xD;
&#xD;
          5. Renal impairment (serum creatinine ≥ 2 times the upper limit of normal (ULN])&#xD;
&#xD;
          6. Aspartate transaminase (AST) and/or alanine transaminase (ALT) ≥ 3 times ULN&#xD;
&#xD;
          7. Increased risk of bleeding (i.e., due to hemophilia, platelet disorders, or use of any&#xD;
             anticoagulation/platelet modifying therapies up to 2 weeks prior to Study Day 1 and&#xD;
             for duration of study; low dose aspirin [≤ 100 mg daily] is permitted)&#xD;
&#xD;
          8. Severe deformity or ankle fixation that would sufficiently limit passive range of&#xD;
             motion to affect assessment of dorsiflexion strength&#xD;
&#xD;
          9. Major surgery within 4 weeks prior to Study Day 1&#xD;
&#xD;
         10. Chronic pharmacologic doses of systemic corticosteroids (≥ 2 weeks) within 4 weeks&#xD;
             before Study Day 1 and for duration of study;&#xD;
             intra-articular/topical/inhaled/intranasal physiologic doses of systemic&#xD;
             corticosteroids are permitted&#xD;
&#xD;
         11. Androgens, growth hormone, insulin or oral hormone replacement therapy within 6 months&#xD;
             before Study Day 1 and for duration of study; topical physiologic androgen replacement&#xD;
             is permitted&#xD;
&#xD;
         12. Any change in medications potentially affecting muscle strength or function within 4&#xD;
             weeks of Study Day 1 and for duration of study (e.g., creatinine, CoQ10, systemic&#xD;
             beta-adrenergic agonists)&#xD;
&#xD;
         13. Previous exposure to any investigational agent potentially affecting muscle volume,&#xD;
             muscle strength, or muscle or nerve function within 5 half-lives of last dose plus an&#xD;
             additional 8-week washout period (or 12 weeks prior to Study Day 1 if half-life is&#xD;
             unknown)&#xD;
&#xD;
         14. Any previous or current exposure to ACE-083&#xD;
&#xD;
         15. Significant change in physical activity or exercise (e.g., significant increase or&#xD;
             decrease in intensity or frequency) within 8 weeks before Study Day 1 or inability to&#xD;
             maintain the baseline level of physical activity throughout the study&#xD;
&#xD;
         16. Any condition that would prevent MRI scanning or compromise the ability to obtain a&#xD;
             clear and interpretable scan of the lower leg, as applicable (e.g., knee/hip&#xD;
             replacement metallic implants)&#xD;
&#xD;
         17. Known active substance abuse, including alcohol&#xD;
&#xD;
         18. History of sensitivity to protein pharmaceuticals&#xD;
&#xD;
         19. Female that is lactating/breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Backstrom, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Acceleron Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California-Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center - Neurology Department</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, Neurology Department</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center, Neurology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System Neurosciences Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <results_first_submitted>March 11, 2021</results_first_submitted>
  <results_first_submitted_qc>July 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 28, 2021</results_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMT1 / CMTX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03124459/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03124459/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part 1 Cohort 1 (150 mg)</title>
          <description>ACE-083 150 mg intramuscular (IM; tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 Cohort 2 (200 mg)</title>
          <description>ACE-083 200 mg IM, (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 Cohort 3 (240 mg)</title>
          <description>ACE-083 240 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="P4">
          <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
          <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
        </group>
        <group group_id="P5">
          <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
          <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
        </group>
        <group group_id="P6">
          <title>Part 2 (Open-label) ACE-083 Arm</title>
          <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 8 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1-Open Label Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0">Patients in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study.</participants>
                <participants group_id="P5" count="0">Patients in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study.</participants>
                <participants group_id="P6" count="0">Patients in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study. Participants that completed the double-blind portion of the study then moved into this Part 2 open-label portion of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0">Patients in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study.</participants>
                <participants group_id="P5" count="0">Patients in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study.</participants>
                <participants group_id="P6" count="0">Patients in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study. Participants that completed the double-blind portion of the study then moved into this Part 2 open-label portion of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2- Randomized Doubled-blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants in Part 1 Open-Label Dose escalation portion of the study were not the same participants that participated in the double-blind placebo controlled study.</participants>
                <participants group_id="P2" count="0">Participants in Part 1 Open-Label Dose escalation portion of the study were not the same participants that participated in the double-blind placebo controlled study.</participants>
                <participants group_id="P3" count="0">Participants in Part 1 Open-Label Dose escalation portion of the study were not the same participants that participated in the double-blind placebo controlled study.</participants>
                <participants group_id="P4" count="21">Participants in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study.</participants>
                <participants group_id="P5" count="24">Participants in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study.</participants>
                <participants group_id="P6" count="0">Participants in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study. Participants that completed the double-blind portion of the study then moved into this Part 2 open-label portion of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2- Open Label ACE-083</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0">Participants in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study. Participants that completed the double-blind placebo controlled portion of Part 2, moved into the open-label portion part 2 study.</participants>
                <participants group_id="P5" count="0">Participants in the double-blind placebo controlled study were not the same participants that participated in the Part 1 Open-Label Dose escalation portion of the study. Participants that completed the double-blind placebo controlled portion of Part 2, moved into the open-label portion part 2 study.</participants>
                <participants group_id="P6" count="40">The open-label portion of Part 2 are the participants that were enrolled in and completed the double-blind placebo-controlled portion of Part 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set includes all randomized patients who have received at least 1 dose of study drug (includes placebo). Additionally, the participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2. The open-label baseline measures are captured separately.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1 Cohort 1</title>
          <description>ACE-083 150 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 Cohort 2</title>
          <description>ACE-083 200 mg IM, (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 Cohort 3</title>
          <description>ACE-083 240 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="B4">
          <title>Part 2 (Double-blind Placebo Controlled) Placebo</title>
          <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - buffer solution.</description>
        </group>
        <group group_id="B5">
          <title>Part 2 (Double-blind Placebo Controlled) ACE-083</title>
          <description>ACE-083 up to 250 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083 Part 2 - Recombinant fusion protein</description>
        </group>
        <group group_id="B6">
          <title>Part 2 (Open-label) ACE 083-03 Arm</title>
          <description>ACE-083 up to 250 mg IM (tibialis anterior muscle) once every 3 weeks for up to 8 doses&#xD;
ACE-083 Part 2 - Recombinant fusion protein</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="40"/>
            <count group_id="B7" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2. The open-label baseline measures are captured separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="24"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="40"/>
                    <count group_id="B7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>One patient in the Phase 2 randomized portion of the study was randomized (to the ACE-083 arm) but not dosed.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="23"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="18.1"/>
                    <measurement group_id="B2" value="39" spread="17.8"/>
                    <measurement group_id="B3" value="49" spread="9.7"/>
                    <measurement group_id="B4" value="47.1" spread="15.3"/>
                    <measurement group_id="B5" value="45.8" spread="11.2"/>
                    <measurement group_id="B7" value="45.3" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="40"/>
                    <count group_id="B7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="47.3" spread="12.9"/>
                    <measurement group_id="B7" value="47.3" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>One patient in the Phase 2 randomized portion of the study was randomized (to the ACE-083 arm) but not dosed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="23"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="40"/>
                    <count group_id="B7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>One patient in the Phase 2 randomized portion of the study was randomized (to the ACE-083 arm) but not dosed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="23"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="40"/>
                    <count group_id="B7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>One patient in the Phase 2 randomized portion of the study was randomized (to the ACE-083 arm) but not dosed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="23"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="40"/>
                    <count group_id="B7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2. The open-label baseline measures are captured separately.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="21"/>
                    <count group_id="B5" value="24"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B7" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>The participants in the Open-Label portion of Part 2 are a sub-set of the participants that enrolled and then subsequently completed the double-blind placebo controlled portion of Part 2.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="40"/>
                    <count group_id="B7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Frequency of Adverse Events</title>
        <description>Number of subjects with at least one adverse event related to treatment intervention from Part 1 of this study. Since this outcome measure was only pre-specified for Part 1, only data from the Part 1 participants is reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period for Part 1 (Study Day 141).</time_frame>
        <population>The Safety Set consists of all patients enrolled in the study who have received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 Cohort 1 (150 mg)</title>
            <description>ACE-083 150 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 Cohort 2 (200 mg)</title>
            <description>ACE-083 200 mg IM, (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 Cohort 3 (240 mg)</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Frequency of Adverse Events</title>
          <description>Number of subjects with at least one adverse event related to treatment intervention from Part 1 of this study. Since this outcome measure was only pre-specified for Part 1, only data from the Part 1 participants is reported.</description>
          <population>The Safety Set consists of all patients enrolled in the study who have received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Percent Change in Muscle Volume to the End of the Double-blind Placebo-controlled Portion of the Study.</title>
        <description>The percent change from baseline in volume of injected muscle, by MRI compared to the Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percent Change in Muscle Volume to the End of the Double-blind Placebo-controlled Portion of the Study.</title>
          <description>The percent change from baseline in volume of injected muscle, by MRI compared to the Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="4.1"/>
                    <measurement group_id="O2" value="15.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.9</ci_lower_limit>
            <ci_upper_limit>22.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Absolute Change in Amount of Intramuscular Fat Tissue to the End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>The absolute change from baseline in intramuscular fat fraction of the injected muscle, by MRI compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Absolute Change in Amount of Intramuscular Fat Tissue to the End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>The absolute change from baseline in intramuscular fat fraction of the injected muscle, by MRI compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>mm3</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="1.8"/>
                    <measurement group_id="O2" value="-2.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percent Change in Muscle Strength to the End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>Percent change from baseline in strength of the injected muscle, by Quantitative Muscle Testing (QMT) compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percent Change in Muscle Strength to the End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>Percent change from baseline in strength of the injected muscle, by Quantitative Muscle Testing (QMT) compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="19.8"/>
                    <measurement group_id="O2" value="32.0" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>35.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>23.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percent Change in Muscle Function - Walk/Run Time to the End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>The percent change from baseline in functional assessments, as measured by 10-meter walk/run time when compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percent Change in Muscle Function - Walk/Run Time to the End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>The percent change from baseline in functional assessments, as measured by 10-meter walk/run time when compared to Day 190 Assessment is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="4.7"/>
                    <measurement group_id="O2" value="-8.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percent Change in Muscle Function - Walk Distance Assessed at the End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>Percent change from baseline in functional assessments, as measured by 6-minute walk distance when compared to Day 190 Assessment, is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period for the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percent Change in Muscle Function - Walk Distance Assessed at the End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>Percent change from baseline in functional assessments, as measured by 6-minute walk distance when compared to Day 190 Assessment, is reported. The pre-specified timepoint for this outcome was only for data collected from participants to the end of the double-blind placebo controlled portion of the study, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="4"/>
                    <measurement group_id="O2" value="9.1" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study.</title>
        <description>Change from baseline in static and dynamic balance, as measured by the Berg Balance Scale, a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of &lt; 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change in Balance and Fall Risk at the End of the Double-blind Placebo-controlled Portion of the Study.</title>
          <description>Change from baseline in static and dynamic balance, as measured by the Berg Balance Scale, a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of &lt; 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" spread="1.99"/>
                    <measurement group_id="O2" value="50.8" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" spread="2.77"/>
                    <measurement group_id="O2" value="51.4" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percent Change in Balance and Fall Risk From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>Percent change was calculated for the difference from baseline and Day 190 Assessment scores on the Berg Balance Scale. The Berg Balance Scale, is a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of &lt; 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percent Change in Balance and Fall Risk From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>Percent change was calculated for the difference from baseline and Day 190 Assessment scores on the Berg Balance Scale. The Berg Balance Scale, is a 14-item scoring system to assess balance and fall risk in adults. The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. It is a 14 item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function. Total scores are used for reporting, with a range of 0-56, with higher scores mean a better demonstration of function. A score of 56 indicates functional balance. A score of &lt; 45 indicates individuals may be at greater risk of falling. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>percent change in score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="3.59"/>
                    <measurement group_id="O2" value="1.3" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change in Clinical Examination Score From Baseline to End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>Change from baseline in the Charcot-Marie-Tooth (CMT) Examination Score, version 2 (CMTES2), a composite scoring system to assess sensory and motor impairment in subjects with CMT. The total score is a subset of the following items from the CMT neuropathy score instrument: Sensory symptoms, Motor symptoms (legs), Motor symptoms (arms), Pinprick Sensibility, Vibration, Strength (legs), and Strength (arms). Each individual item is assessed using a rating from 0 to 4 inclusive. The range of CMTES2 scores is from 0 to 28 inclusive. A higher score means a greater degree of symptom severity. The Baseline score and score on the Day 190 Assessment are reported. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change in Clinical Examination Score From Baseline to End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>Change from baseline in the Charcot-Marie-Tooth (CMT) Examination Score, version 2 (CMTES2), a composite scoring system to assess sensory and motor impairment in subjects with CMT. The total score is a subset of the following items from the CMT neuropathy score instrument: Sensory symptoms, Motor symptoms (legs), Motor symptoms (arms), Pinprick Sensibility, Vibration, Strength (legs), and Strength (arms). Each individual item is assessed using a rating from 0 to 4 inclusive. The range of CMTES2 scores is from 0 to 28 inclusive. A higher score means a greater degree of symptom severity. The Baseline score and score on the Day 190 Assessment are reported. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="3.4"/>
                    <measurement group_id="O2" value="10.9" spread="3.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="3.02"/>
                    <measurement group_id="O2" value="11.2" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Percent Change in Clinical Examination Score in Baseline to End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>Percent change was calculated for the difference in the Charcot-Marie-Tooth (CMT) Examination Score (CMTES2) from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Percent Change in Clinical Examination Score in Baseline to End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>Percent change was calculated for the difference in the Charcot-Marie-Tooth (CMT) Examination Score (CMTES2) from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations.</population>
          <units>percent change in score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="34.63"/>
                    <measurement group_id="O2" value="2.4" spread="24.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Change in Patient-reported Quality of Life From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study</title>
        <description>The absolute change from baseline in Charcot-Marie-Tooth Health Index (CMT-HI), a disease-specific, patient-reported health index score from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
        <time_frame>From initiation of treatment (Study Day 1) to end of follow-up period of the double-blind placebo-controlled portion of the study (Study Day 190).</time_frame>
        <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
            <description>Placebo once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 -buffer solution</description>
          </group>
          <group group_id="O2">
            <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
            <description>ACE-083 240 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083: Part 2 - Recombinant fusion protein</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change in Patient-reported Quality of Life From Baseline to the End of the Double-blind Placebo-controlled Portion of the Study</title>
          <description>The absolute change from baseline in Charcot-Marie-Tooth Health Index (CMT-HI), a disease-specific, patient-reported health index score from baseline and Day 190 Assessment scores. The pre-specified timepoints for reporting are baseline Berg scale score and Day 190 score, therefore data for the open-label arm of the study is not reported.</description>
          <population>Per Protocol Set: All participants enrolled/randomized in the study who received at least 1 dose of the study drug (includes placebo) with no major protocol violations</population>
          <units>absolute change in score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.3"/>
                    <measurement group_id="O2" value="-2.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1 adverse events (AEs) were collected from baseline through Day 141. For Part 2, AEs were collected from on or after the first double-blind study drug administration up to the end of the double-blind period (Day 190). For the open-label period, adverse events are defined as AEs that started or worsened in intensity on or after the first open-label study drug administration up to the end of the study(Day 393/end-of-study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1 Cohort 1(150mg)</title>
          <description>ACE-083 150 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 Cohort 2 (200mg)</title>
          <description>ACE-083 200 mg IM, (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 Cohort 3 (250mg)</title>
          <description>ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.&#xD;
ACE-083: Part 1 - Recombinant fusion protein.</description>
        </group>
        <group group_id="E4">
          <title>Part 2 (Double-blind Placebo Controlled) Placebo Arm</title>
          <description>Placebo, once every 3 weeks for up to 9 doses&#xD;
ACE-083:&#xD;
Part 2 - Placebo: buffer solution</description>
        </group>
        <group group_id="E5">
          <title>Part 2 (Double-blind Placebo Controlled) ACE-083 Arm</title>
          <description>ACE-083 up to 250 mg IM (tibialis anterior muscle) once every 3 weeks for up to 9 doses&#xD;
ACE-083:&#xD;
Part 2 - Recombinant fusion protein</description>
        </group>
        <group group_id="E6">
          <title>Part 2 (Open Label)</title>
          <description>ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses&#xD;
ACE-083: Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEdDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>inflammation of lacrimal passage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site discoloration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site macule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site dysaethesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>medical device site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>pneunomia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>sinobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>exposure to communicable disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>crystal urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>myoglobin blood increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>thyroxine free increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>urine analysis abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>decreased appetitie</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>muscle spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>joint instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>rhinorrheoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>snoring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>skin warm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>mechanical urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>pseudofolliculitis barbae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Behcet's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated because the statistically significant increase in total muscle volume (TMV) failed to translate to statistically significant improvements in functional or disease-related quality of life secondary endpoints in the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>SVP Regulatory Affairs</name_or_title>
      <organization>Acceleron Pharma Inc.</organization>
      <phone>617-649-9200</phone>
      <email>jdesiderio@acceleronpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

